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PERSPECTIVE OPEN
The Breathing, Thinking, Functioning clinical model: a
proposal to facilitate evidence-based breathlessness
management in chronic respiratory disease
Anna Spathis1,2, Sara Booth2, Catherine Moffat1, Rhys Hurst1, Richella Ryan2, Chloe Chin1 and Julie Burkin1
Refractory breathlessness is a highly prevalent and distressing symptom in advanced chronic respiratory disease. Its intensity is not
reliably predicted by the severity of lung pathology, with unhelpful emotions and behaviours inadvertently exacerbating and
perpetuating the problem. Improved symptom management is possible if clinicians choose appropriate non-pharmacological
approaches, but these require engagement and commitment from both patients and clinicians. The Breathing Thinking
Functioning clinical model is a proposal, developed from current evidence, that has the potential to facilitate effective symptom
control, by providing a rationale and focus for treatment.
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INTRODUCTION
Breathlessness is prevalent in chronic respiratory disease, and
primary care bears much of the burden of its management. Over
80% of patients in the community with chronic obstructive
pulmonary disease (COPD), for example, experience some degree
of breathlessness.1, 2 It is a debilitating symptom, with a negative
impact on quality of life, psychological wellbeing and functional
status.3 Multiple observational studies link breathlessness with
anxiety and depression.4, 5 Carers also suffer significantly,
burdened by distress, social isolation and a devastating sense of
helplessness.6
The management of breathlessness is hampered by its inherent
complexity. Optimising treatment of the underlying disease has an
inconsistent impact on the symptom. There are a plethora of non-
pharmacological approaches to ameliorate breathlessness, with-
out evidence to guide individualisation of therapy. Furthermore,
understandable, but unhelpful, reactions to the perception of
breathlessness unwittingly compound the symptom.
In this paper, we explore this complexity and outline a proposal,
developed from current evidence, on how to overcome it using
the Breathing, Thinking, Functioning (BTF) clinical model.
Although we focus on breathlessness management in COPD, this
pragmatic clinical approach can be used in any advanced cardio-
respiratory disease.
UNDERSTANDING THE COMPLEXITY
Relationship between disease and breathlessness severity
Breathlessness severity is not reliably predicted by the severity of
airflow limitation in COPD. Multiple studies have shown marked
variation in the perception of breathlessness, for a given level of
lung function.7, 8 An observational study of almost 50,000 patients
with COPD in the UK revealed that a third of those with stage 1
disease described moderate to severe breathlessness, whereas
over 20% of those with stage 4 disease did not have clinically
significant breathlessness.2 In a recent controlled trial, broncho-
scopic lung volume reduction significantly improved FEV1 by 25%,
without relief of breathlessness.9
The inconsistent relationship between pathology and breath-
lessness perception explains why optimising disease management
alone does not guarantee good symptom control. This discre-
pancy has led to a number of terms suggesting exaggerated
symptom perception, such as ‘disproportionate breathlessness’,
‘breathlessness out of keeping with pathology’ and ‘medically
unexplained breathlessness’. It is apparent that there must be
factors influencing breathlessness beyond that expected due to
the underlying disease.
Neurophysiology of breathlessness
Neuroimaging studies over the last decade have significantly
increased understanding of the neural processing of the sensation
of breathlessness, and the range of factors influencing the
symptom perception.10, 11 Demand for ventilation, sensed by
chemo-receptors and metabo-receptors, is compared with affer-
ent information on actual ventilation from widespread sources,
including pulmonary stretch receptions, pulmonary C fibres, chest
wall joint and skin receptors, and skeletal muscle ergoreceptors.12
Breathlessness perception is believed to be driven by a mismatch
between the two.13, 14 Neural integration occurs in cortico-limbic
regions of the brain, which are influenced by thoughts and
emotions, further modulating breathlessness perception.11, 15
A consequence of this neural complexity is that it limits the
potential for a single effective intervention, a point supported by
an increasing body of literature (Table 1). Oxygen therapy,
although it reverses hypoxaemia, does not improve breathlessness
in patients with cancer, and the marginal benefit seen in a meta-
analysis of COPD patients is of dubious clinical significance.16, 17
Benzodiazepines are widely used, but do not improve breath-
lessness.18 Even opioids, with most evidence to support their use,
provide benefit of only borderline clinical significance.19, 20
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Instead the most successful interventions appear to be multi-
modal, non-pharmacological approaches that work concurrently
at multiple points within the brain, respiratory and skeletal
system.21–23 There is strong evidence, for example, that pulmonary
rehabilitation, involving exercise, education and support over
many weeks, leads to clinically significant reduction in breath-
lessness, as well as substantial improvements in fatigue, emotional
functioning and quality of life.24 Approaches incorporating
cognitive behavioural therapy ameliorate breathlessness, as well
as anxiety and depression.21 Evidence is emerging for the
effectiveness of breathlessness services, providing a range of
predominantly non-pharmacological approaches, such as breath-
ing and relaxation techniques, use of a handheld fan, cognitive
behavioural therapy, activity management and carer support.
Table 1. Summary of key evidence for approaches to the management of breathlessness in advanced disease
Reference Description Impact on breathlessness and other key outcomes
Non pharmacological approaches
Bausewein et al.
200822
Cochrane systematic review of 47 controlled studies (2532
participants) evaluating non-pharmacological approaches in any
advanced disease. Studies evaluating pulmonary rehabilitation,
exercise and self-management education excluded
High strength of evidence for neuromuscular electrical
stimulation and chest wall vibration
Moderate strength of evidence for walking aids and breathing
retraining
Low strength of evidence for acupuncture/pressure
Zwerink et al. 2014 Cochrane systematic review of 28 controlled studies evaluating
self-management interventions in COPD
Significant reduction in breathlessness and respiratory-related
hospital admissions
Improved health-related quality of life
Howard et al.
201421
Randomised controlled trial involving 222 COPD patients
allocated to receive a cognitive-behavioural manual (applying
CBT techniques within a self-management framework, with brief
telephone support) or an information booklet
Significant improvement in breathlessness at 6 months
(secondary outcome)
Reduction in A&E visits by 42% with associated cost-savings,
improved anxiety, depression
McCarthy et al.
201524
Cochrane systematic review of 65 randomised controlled trials
evaluating pulmonary rehabilitation in COPD
Moderately large and clinically significant improvement in
breathlessness.
Also improvements in fatigue, quality of life and emotional
function
Pharmacological approaches
Abernethy et al.
200319
Randomised controlled crossover trial of oral morphine
sustained release 20mg twice daily for 4 days vs. placebo,
involving 48 opioid-naive participants
6.6–9.5% improvement in breathlessness
More distressing constipation in the opioid group despite
laxatives
Abernethy et al.
201043
Randomised controlled trial of 239 participants (152 with COPD)
with life-limiting illness, 2 l/min oxygen or room air via a
concentrator for at least 15 h/day
Improvement in both oxygen and room air group, but no
significant differences between groups
Barnes et al.
201620
Cochrane systematic review of 26 controlled trials evaluating
opioids for refractory breathlessness in any advanced disease
Low quality evidence of improvement in post-treatment
breathlessness, but no statistically significant change of
breathlessness from baseline
Simon et al. 201018 Cochrane systematic review of seven controlled trials evaluating
benzodiazepines in advanced malignant or non-malignant
disease
No beneficial effect of benzodiazepines, including from a
meta-analysis of six of the seven studies
Uronis et al.
200816, 44
Systematic review and meta-analysis of five studies evaluating
oxygen for dyspnoea in mildly- or non-hypoxaemic cancer
patients
Oxygen did not improve breathlessness
Ekstrom et al.
201617
Cochrane systematic review of 33 randomised controlled trials
evaluating oxygen for dyspnoea in patients with COPD who do
not qualify for home oxygen therapy
Oxygen improved breathlessness by the equivalent of 0.7 cm
in a 10 cm visual analogues scale, on exercise only.
There was no benefit from oxygen before exercise, and no
improvement in quality of life.
Complex interventions from specialist breathlessness services
Bredin et al. 199945 Randomised controlled trial of 119 patients with lung cancer
receiving a nurse-led, non-pharmacological, outpatient
intervention or best supportive care
Significant improvement in breathlessness, as well as
performance status, anxiety and depression, at 8 weeks
Farquhar et al.
201425
Randomised controlled trial involving 67 cancer patients,
receiving the Breathlessness Intervention Service
(multidisciplinary team providing predominantly home-based,
non-pharmacological approaches) or usual care
Distress from breathlessness improved significantly (primary
outcome) at 2 weeks
Evidence of cost-effectiveness
Higginson et al.
201426
Randomised controlled trial involving 105 patients with mixed
advanced disease, receiving Breathlessness Support Service
(multidisciplinary team providing predominantly outpatient and
home-based, predominantly non-pharmacological approaches)
or usual care.
Mastery of breathlessness improved significantly by an
average of 16% (primary outcome), at 6 weeks
Significant improvement in survival in the intervention group
Johnson et al.
201527
Randomised controlled trial involving 156 cancer patients
receiving either three or a single breathing technique training
session
Improvement in worst breathlessness in last 24 h in both
groups, but not difference between groups
The single session was cost-effective
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Such services provide a brief, cost-effective intervention that
impacts positively on distress from breathlessness, mastery,
quality of life, and even survival.25–27
Reactions to breathlessness
There is growing evidence for a further level of complexity: the
human reaction to the perception of breathlessness may worsen
the symptom. Comroe, an eminent cardiologist, showed great
prescience when he wrote in 1966 that breathlessness ‘involves
both the perception of the sensation by the patient and his
reaction to it…’
Neuroimaging studies reveal that breathlessness activates
cortico-limbic areas, particularly the right anterior insula.10, 11
These regions subserve awareness of threats such as thirst,
hunger, acute pain and breathlessness. Interoceptive awareness of
an acute homoeostatic threat leads to an avoidance behaviour
motivated by emotion, which, in evolutionary terms, clearly
confers a survival advantage. However, in the context of chronic
perceived threats such as persistent breathlessness, such emo-
tions and behaviours can be unhelpful and inadvertently
perpetuate the problem. For example, attempting to avoid the
perception of breathlessness by reducing activity, leads to
deconditioning that, in turn, worsens breathlessness. Decondition-
ing could, in part, explain the evidence in longitudinal studies for
progression in breathlessness severity, despite stable lung
function.28
In a context where optimising management of the underlying
disease is insufficient, where no single effective intervention for
breathlessness exists, and where patients and clinicians risk being
overwhelmed by a myriad of non-pharmacological approaches,
crucially, these inadvertently unhelpful reactions provide a
valuable opportunity to intervene.
THE BTF CLINICAL MODEL
The model is based on three predominant cognitive and
behavioural reactions to breathlessness that, by causing vicious
cycles, worsen and maintain the symptom (Fig. 1).
Breathing domain
Dysfunctional breathing patterns are well recognised in breathless
individuals without underlying respiratory pathology.29 Features
include apical breathing, higher ratio of inspiratory to expiratory
length, absence of end-expiratory pause and frequent sighs or
yawns.30 Breathing pattern disorders occur in about a third of
asthma patients,31 and although there has been no research in
other respiratory conditions, such as COPD, there is extensive
anecdotal evidence that dysfunctional breathing patterns do
occur. Breathless patients experience a sense of ‘needing more air’
and, therefore, may consciously or subconsciously increase their
tidal volume or respiratory rate, breathing predominantly using
the upper chest and accessory muscles. Apical breathing causes
reliance on fatiguable accessory muscles of respiration, under-
utilising the efficient and relatively fatigue-resistant diaphragmatic
muscle, further increasing the work of breathing and intensifying
breathlessness.32
Thinking domain
It is well-recognised that the anxiety or fear caused by breath-
lessness can, in turn, augment the perception of breathlessness.33
This vicious cycle can lead to a rapidly escalating sense of panic,
which most breathless patients experience at some point. The
neural processing for this feedback loop is likely to occur in the
cortico-limbic areas of the brain, involved in both breathlessness
perception and processing of emotion.34 In addition, anxiety
increases the respiratory rate and can cause muscle tension in
both the ventilatory pump and other skeletal muscles, so further
increasing the work of breathing and respiratory demand.
Functioning domain
As breathlessness is so unpleasant, it is natural to avoid it by
reducing activity. However, inactivity leads to muscle decondition-
ing, with reduced oxidative capacity, muscle fibre atrophy and
fibre type shift from type 1 (oxidative) to type IIb (glycolytic)
fibres.35 This increases the demand on the respiratory system, and
worsens breathlessness further. Patients intuitively understand
Fig. 1 The Breathing, Thinking, Functioning clinical model
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this ‘deconditioning vicious cycle’, being aware that less ‘fit’
people are more breathless on exertion. Family members and
other carers can unwittingly compound the situation, by trying to
help through doing activities that the patient might otherwise
have done.
Model development
This empirical model was developed by the Cambridge Breath-
lessness Intervention Service (CBIS), a multidisciplinary home-
based intervention of proven cost-effectiveness.25 Each of the
three domains is supported by research evidence, as described
above, and the model is theoretically underpinned by a ‘vicious
flower’ maintenance model formulation, widely used in
cognitive–behavioural therapy within psychological medicine.36
It was initially conceived in 2012 for use as an educational tool
for healthcare staff, to explain mechanisms worsening breath-
lessness beyond the underlying respiratory condition, and to
facilitate choice of non-pharmacological techniques to interrupt
each vicious cycle. As well as being enthusiastically endorsed by
healthcarers for providing a conceptually clear approach to the
management of a complex symptom, service evaluations and
anecdotal evidence from clinical utilisation within CBIS are
revealing unanticipated benefits for patients and their families.
POTENTIAL ROLES IN SUPPORTING SELF-MANAGEMENT IN
PRIMARY CARE
Explaining and engaging
The evidence is clear that when individuals with a chronic
condition, like COPD, actively participate in their own care through
self-management, their medical outcomes improve.37, 38 Non-
pharmacological interventions are under-utilised, not least
because patients need commitment to make and sustain
behaviour change. Providing a clear and logical rationale for
symptom deterioration, or perpetuation beyond an initial trigger,
can be profoundly motivating.
Patients, furthermore intuitively comprehend that a vicious
cycle can be broken, turning instead into a ‘cycle of improvement’.
The ‘small changes approach’, accepted as a particularly effective
and feasible way of achieving behavioural change, develops the
potential to generate rapid and large gains.39 Enhancing self-
efficacy is a particularly effective way to support self-
management.40
Engaging healthcare professionals is equally vital. Clinical
training prioritises disease-modification over symptom control
and, unlike allied health professionals, doctors are rarely taught
how to support behaviour change. The focus is on prescribing, a
relatively simple, culturally acceptable and passive practice
compared to the time, energy and cohesive teamwork required
to deliver non-pharmacological therapies. Providing a rationale,
not just for the presence of the symptom, but also for why
it should be amenable to intervention, can be helpful for
clinicians too.
Facilitating and focusing management
Patients with intractable breathlessness are commonly fatigued,
which limits the capacity to retain and process new information.41
The more information presented in a consultation, the lower the
proportion that is correctly recalled.42 The wide array of potentially
effective non-pharmacological interventions for breathlessness fit
neatly within the three domains of the clinical model (Table 2).
Clinical experience shows that, although all three vicious cycles
occur to a degree in each breathless patient, in practice, one or
two tend to predominate. Focusing on those interventions which
impact on the predominant cycle can increase adherence and,
importantly, provide early ‘quick wins’ that further contribute to
patient engagement and self-efficacy. Simply, for example,
compassionately challenging one of the misconceptions driving
a predominant vicious cycle (Fig. 2) can, in itself, be highly
effective and time-efficient in a busy healthcare setting.
NEXT STEPS
Although, as described, the model underpins the delivery of an
evidence-based intervention and each of the three domains are
supported by research evidence, formal research evaluation of the
model is required. A mixed-methods approach is planned.
Phenomenological qualitative research methods, with in-depth
interviews and focus groups, will gather and triangulate insights
from patients, carers and healthcare staff, in terms of experiences
of using the model and attributed meaning. As anecdotal
evidence suggests that the model could have a particular role in
facilitating brief community-based intervention, a cluster-
randomised trial will be undertaken to evaluate the cost-
effectiveness of a single intervention for patients with COPD in
primary care. It will initially be tested in patients with severe
disease who remain symptomatic after, or could not
complete, pulmonary rehabilitation, and those considered, but
ineligible, for invasive procedures like lung volume reduction or
transplant. Key outcomes will include changes in perceived self-
efficacy in symptom management, in the rate of primary care
consultations and in the number of contacts with emergency
services out of hours.
CONCLUSION
Insight into the many factors influencing breathlessness in chronic
respiratory disease, including the inadvertently unhelpful reac-
tions that exacerbate it, provide a valuable opportunity to
intervene.
We propose that the BTF model not only explains how
breathlessness perpetuates and worsens, but also provides a
structure and rationale for its management—through generating
the antithesis of vicious cycles, ‘cycles of improvement’—thereby
engaging patients and professionals alike. Given the availability of
diverse non-pharmacological approaches, the model potentially
provides direction and focus to initial management, facilitating the
provision of personalised therapy.
Table 2. Categorisation of symptom management approaches according to Breathing, Thinking, Functioning domain
Breathing Thinking Functioning
Breathing techniques Cognitive behavioural therapy Pulmonary rehabilitation
Handheld fan Relaxation techniques Activity promotion
Airway clearance techniques Mindfulness Walking aids
Inspiratory muscle training Acupuncture Pacing
Chest wall vibration Neuromuscular electrical stimulation
Non-invasive ventilation
The breathing, thinking, functioning clinical model
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Approaches that promote self-management are known to
benefit people with chronic conditions. Time-pressured clinical
settings require a brief intervention that targets the specific
mechanisms driving an individual’s symptoms. The BTF model has
the potential to fulfil all these needs, and may be particularly
relevant in community settings. Further research is required to
clarify its effectiveness.
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